Brief: Timber Pharmaceuticals Announces Publication Of Results From Phase 2B Control Study Of FDA-Designated Breakthrough Therapy Tmb-001
26/08/2022 14:07
Aug 26 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS ANNOUNCES PUBLICATION OF RESULTS
FROM
PHASE 2B CONTROL STUDY OF FDA-DESIGNATED BREAKTHROUGH THERAPY
TMB-001 IN THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Source text for Eikon: ID:nGNX9jmNR3
Further company coverage: TMBR.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing